Cook MyoSite
Cook MyoSite specializes in the development, manufacturing, and global distribution of human muscle-derived cell technologies for research and clinical applications. The company is experienced in clinical trial execution, GMP cell therapy manufacturing, analytical testing, donor tissue procurement across rare and neuromuscular disorders, and custom media solutions. Their technology platform supports regenerative medicine innovations and muscle-related research, with a focus on autologous therapies and quality control for translational and preclinical studies.
Cook MyoSite
100 Delta Drive Pittsburgh, PA 15238
Patents
Methods, substrates, and systems useful for cell seeding of medical grafts
2024-10-22 • US-12121631-B2
View DetailsWhat We Do
Single-donor, characterized primary human skeletal muscle myoblast-like cells for fundamental and disease-specific research. Includes access to donor tissue from both healthy individuals and those with neuromuscular, metabolic, and rare disorders such as myotonic dystrophy, Guillain-Barre syndrome, Marfan syndrome, and Friedrich's ataxia, with robust metadata and clinical history available.
Purified human primary fibro-adipogenic progenitor cells suitable for modeling muscle regeneration, fibrosis, adipogenesis, and disease across multiple donor backgrounds.
Tailored products and custom solutions, including procurement of specific donor tissue (healthy or disease), custom lot manufacturing, and unique media formulation.
Basal, differentiation, cryopreservation, serum-free, and insulin-free media designed for primary muscle cell growth and differentiation.
Manufacturing of muscle and other adherent cell types, including GMP and non-GMP scale-up, cryopreservation, and process development, tailored for research or clinical partners.
QC and specialized analytical services including sterility, viability, gene expression, and identity assays for cell and biologic samples.
Application Area
Show LessDigital Health Technologies
Key People
President
News & Updates
Laboratory research services manufactured under an ISO9001:2015 Certified Quality Management System.
Three separate RMAT designations awarded by the FDA for autologous muscle-derived cell therapies in stress urinary incontinence, fecal incontinence, and oropharyngeal dysphagia.
A compilation of peer-reviewed publications related to the muscle-derived cell therapy technology and its research applications.
Discussion of comparative advantages of primary human muscle cells over immortalized cell lines in research applications.
Expert opinions on the application and future of regenerative medicine in the field of urology.
Initiation of participant treatment in a Phase III trial evaluating safety and efficacy of autologous muscle-derived cells for chronic fecal incontinence in women with obstetric anal sphincter injury.